Journal
VIROLOGY JOURNAL
Volume 18, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s12985-021-01589-x
Keywords
Hepatitis B virus; HBsAg clearance; Prognosis
Categories
Funding
- Thirteenth Five-Year Major Science and Technology Projects [2017ZX10202201, 2017ZX10201021-001-008, 2017ZX10302201-004-003, 2017ZX10202202-005-010]
- Capital Health Research and Development Projects [2020-1-2181]
- Chinese National Natural Science Foundation [81900537]
- Key R&D and transformation plan in Qinghai Province [2017-SF-159]
- Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support [ZYLX202125]
- Beijing Hospitals Authority Clinical Medicine Development of Special Funding Support [XMLX202125]
Ask authors/readers for more resources
HBsAg clearance is considered the ideal endpoint for antiviral treatment, with recent advances in combined and extended treatment strategies improving clearance rates. However, durability and clinical outcomes post-clearance remain areas of focus for researchers and clinicians.
Hepatitis B surface antigen (HBsAg) clearance is regarded as the ideal endpoint for antiviral treatment in terms of drug withdrawal safety and improvements in prognosis. However, the overall rate of HBsAg clearance is low and differs based on treatment method and course. The recent application of combined and extended treatment strategies have improved the HBsAg clearance rate, and several patients achieved HBsAg clearance in clinical treatment. In addition, the durability of and clinical outcomes after HBsAg clearance have become the focus of both researchers and clinicians. This article reviews HBsAg clearance in terms of accessibility, durability, improvements in prognosis and relevant advances.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
